News und Analysen
![Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data
Veeva Systems (NYSE: VEEV) (“Veeva”) and Bioforum today announced their collaboration with RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill”) on a global Phase 2/3 clinical study evaluating opaganib
![Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)
Quantum Genomics to receive up to $19 million in upfront and milestone payments plus double-digit royalties on sales
OEP to receive an exclusive license to develop and commercialize firibastat for
![Medigene AG: Strategic measures including restructuring with extension of cash runway and improved EBITDA](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Medigene AG: Strategic measures including restructuring with extension of cash runway and improved EBITDA
Business news for the stock market
Planegg/Martinsried (22.09.2020) - 22 September 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing
![Medigene AG: Strategische Maßnahmen inklusive Restrukturierung mit Verlängerung der Finanzierungsreichweite und verbessertem EBITDA](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Medigene AG: Strategische Maßnahmen inklusive Restrukturierung mit Verlängerung der Finanzierungsreichweite und verbessertem EBITDA
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (22.09.2020) - 22. September 2020. Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit
![Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2020. The
![Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
![Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States
DexCom, Inc. (NASDAQ:DXCM) announced today the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now available at Veterans Affairs (VA) pharmacies, improving access to CGM and empowering
![Relay Medical gründet Clinical Advisory Board und Strategic Advisory Board](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Relay Medical gründet Clinical Advisory Board und Strategic Advisory Board
22. September 2020. Relay Medical Corp. (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) („Relay“ oder das „Unternehmen“), ein Entwickler von Medtech-Innovationen, freut sich, über die Gründung eines
![Relay Medical Forms Clinical and Strategic Advisory Boards](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Relay Medical Forms Clinical and Strategic Advisory Boards
September 22, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, is pleased to report on the formation of a Cli
![Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA
Waters Corporation (NYSE:WAT) announced this week at Biotech Week Boston the establishment of Immerse™ Cambridge, a new Waters' research laboratory in the heart of Cambridge’s Kendall Square
![Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
![Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement Globally](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement Globally
Veeva Systems (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has selected Veeva Commercial Cloud to enable its digital field force in the U.S., Japan, and countries
![Medis Selects Veeva CRM to Deliver Personalized Experiences to Healthcare Professionals](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Medis Selects Veeva CRM to Deliver Personalized Experiences to Healthcare Professionals
Veeva Systems (NYSE: VEEV) today announced that Medis has switched to multichannel Veeva CRM in 15 countries across Central and Eastern Europe to advance its commercial strategy and drive more
![VALBIOTIS wurde von der European Association for the Study of Diabetes (EASD) zur Vorstellung von drei Studien zu TOTUM-63 ausgewählt](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
VALBIOTIS wurde von der European Association for the Study of Diabetes (EASD) zur Vorstellung von drei Studien zu TOTUM-63 ausgewählt
Aufsichtsrechtliche Nachrichten:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher
![EnWave unterzeichnet ein Technologiebewertungs- und Lizenzoptionsabkommen mit Extrx OY](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EnWave unterzeichnet ein Technologiebewertungs- und Lizenzoptionsabkommen mit Extrx OY
Vancouver, British Columbia. 21. September 2020, EnWave Corporation (TSX-V: ENW | FSE: E4U) („EnWave“ oder das „Unternehmen“ - https://www.commodity-tv.com/ondemand/companies/profil/enwave-c
![EnWave Signs Technology Evaluation and License Option Agreement with Extrx OY](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EnWave Signs Technology Evaluation and License Option Agreement with Extrx OY
Vancouver, B.C., September 21st, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
![Illumina to Acquire GRAIL to Launch New Era of Cancer Detection](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
![VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating
![ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in
![American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation
American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval
![Sensorion beschafft rund 31 Millionen Euro (36,5 Millionen US-Dollar) durch eine überzeichnete Privatplatzierung bei US-amerikanischen und europäischen Investoren](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Sensorion beschafft rund 31 Millionen Euro (36,5 Millionen US-Dollar) durch eine überzeichnete Privatplatzierung bei US-amerikanischen und europäischen Investoren
Nicht für direkte oder indirekte Freigabe, Veröffentlichung oder Verteilung in bzw. nach den USA, Kanada, Australien oder Japan bestimmt. Diese Pressemitteilung stellt kein Angebot dar und dient
![Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and
![Sensorion beginnt Kapitalerhöhung durch beschleunigtes Bookbuilding-Verfahren](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sensorion beginnt Kapitalerhöhung durch beschleunigtes Bookbuilding-Verfahren
Nicht für direkte oder indirekte Freigabe, Veröffentlichung oder Verteilung in bzw. nach den USA, Kanada, Australien oder Japan bestimmt. Diese Pressemitteilung stellt kein Angebot dar und dient
![Vifor Pharma Group Announces Successful Sale of OM Pharma](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Vifor Pharma Group Announces Successful Sale of OM Pharma
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal
![QIAGEN übernimmt NeuMoDx Molecular, Inc. und vervollständigt sein Portfolio an PCR-basierten Automatisierungssystemen für die Diagnostik](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
QIAGEN übernimmt NeuMoDx Molecular, Inc. und vervollständigt sein Portfolio an PCR-basierten Automatisierungssystemen für die Diagnostik
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute den Erwerb der verbliebenen 80,1 % der Anteile an NeuMoDx Molecular, Inc., einem Entwickler von Diagnostikinstrumenten, gegen eine